The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious…
- J. Bradley, C. Byington, J. Swanson
- MedicineClinical Infectious Diseases
- 1 October 2011
Abstract Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators…
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
- T. Pilishvili, C. Lexau, M. Moore
- Medicine, BiologyJournal of Infectious Diseases
- 2010
Dramatic reductions in IPD after PCV7 introduction in the United States remain evident 7 years later, and IPD rates caused by serotype 19A and other non-PCV7 types have increased but remain low relative to decreases in PCV 7-type IPD.
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
- M. Moore, R. Link-Gelles, C. Whitney
- MedicineLancet. Infectious Diseases (Print)
- 1 March 2015
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices…
- S. Tomczyk, N. Bennett, T. Pilishvili
- MedicineMMWR. Morbidity and mortality weekly report
- 19 September 2014
New recommendations for PCV 13 use are outlined, guidance for use of PCV13 and PPSV23 among adults aged ≥65 years is provided, and the evidence considered by ACIP to make this recommendation is summarized.
Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites
- D. Feikin, E. Kagucia, M. Moore
- Biology, MedicinePLoS Medicine
- 1 September 2013
In a pooled analysis of data collected from invasive pneumococcal disease surveillance databases, Daniel Feikin and colleagues examine serotype replacement after the introduction of 7-valent…
Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.
- R. Pai, M. Moore, T. Pilishvili, R. Gertz, C. Whitney, B. Beall
- Medicine, BiologyJournal of Infectious Diseases
- 1 December 2005
Serotype 19A is, at present, the most important cause of IPD by replacement serotypes, and it is increasingly drug resistant, and some of the increase in rates of infection with serotypes may be due to serotype switching within certain vaccine type strains.
Shifting genetic structure of invasive serotype 19A pneumococci in the United States.
- B. Beall, R. Gertz, Rachel L. Hulkower, C. Whitney, M. Moore, A. Brueggemann
- Medicine, BiologyJournal of Infectious Diseases
- 15 May 2011
Sero19A rates may have plateaued; however, clonal shifts are increasing resistance, and increased IPD caused by CC320/271( 19A) and CC695(19A) could reflect additional selective advantages in addition to resistance.
Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the…
- J. Bradley, C. Byington, J. Swanson
- MedicineClinical Infectious Diseases
- 2011
These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings.
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
- Miwako Kobayashi, N. Bennett, T. Pilishvili
- MedicineMMWR. Morbidity and mortality weekly report
- 4 September 2015
The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two Vaccine Advisory Committee on Immunization Practices (ACIP) currently recommends.
Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco.
- E. Charlebois, D. Bangsberg, F. Perdreau-Remington
- Medicine, BiologyClinical Infectious Diseases
- 15 February 2002
A population-based community sample of 833 homeless and marginally housed adults were cultured and compared with 363 clinical isolates of MRSA, finding that 22.8% of the urban poor were colonized with S. aureus, and resistance to antimicrobials other than beta-lactams was uncommon.
...
...